Skip to main content

Table 1 Baseline characteristics of study participants according to glucose status and prior cerebrovascular diseases

From: Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese

Characteristics

Normoglycemia

P-value

Border

P-value

Diabetes

P-value

Prior CVD(-)

Prior CVD( +)

Prior CVD(-)

Prior CVD( +)

Prior CVD(-)

Prior CVD( +)

n = 209,120

n = 1314

n = 118,693

n = 1240

n = 32,426

n = 834

Age (y)

43.6 ± 9.1

51.3 ± 8.8

 < 0.001

48.6 ± 8.5

55.1 ± 8 .0

 < 0.001

51.9 ± 8.1

56.9 ± 7.4

 < 0.001

BMI (kg/m2)

23.0 ± 3.0

23.4 ± 3.0

 < 0.001

24.2 ± 3.4

24.9 ± 3.3

 < 0.001

26.2 ± 4.3

26.2 ± 4.2

0.810

SBP (mmHg)

119.8 ± 13.9

123.1 ± 14.0

 < 0.001

124.1 ± 15.1

127.1 ± 15.0

 < 0.001

129.9 ± 16.4

131.1 ± 15.8

0.034

DBP (mmHg)

74.8 ± 10.8

77.8 ± 10.5

 < 0.001

78.4 ± 11.1

80.3 ± 10.2

 < 0.001

80.9 ± 11.1

80.2 ± 10.6

0.040

HbA1c (mmol/mol)

34.1 ± 2.5

34.4 ± 2.5

 < 0.001

38.4 ± 3.4

38.9 ± 3.3

 < 0.001

54.3 ± 14.9

52.2 ± 13.0

 < 0.001

FPG (mmol/L)

4.95 ± 0.35

5.01 ± 0.35

 < 0.001

5.64 ± 0.50

5.70 ± 0.50

 < 0.001

7.9 ± 2.2

7.6 ± 2.0

0.005

LDL cholesterol (mmol/L)

3.12 ± 0.78

3.02 ± 0.77

 < 0.001

3.32 ± 0.80

3.11 ± 0.79

 < 0.001

3.20 ± 0.84

2.92 ± 0.85

 < 0.001

HDL cholesterol (mmol/L)

1.53 ± 0.38

1.52 ± 0.37

0.829

1.48 ± 0.38

1.45 ± 0.37

0.004

1.37 ± 0.36

1.38 ± 0.34

0.556

Triglycerides (mmol/L)

1.04 (0.73–1.51)

1.08 (0.78–1.55)

0.006

1.25 (0.87–1.83)

1.30 (0.93–1.83)

 < 0.001

1.47 (1.02–2.19)

1.35 (0.96–2.01)

 < 0.001

Current smoking (%)

78,552 (37.6)

264 (20.1)

 < 0.001

44,319 (37.3)

267 (21.5)

 < 0.001

13,227 (40.8)

207 (24.8)

 < 0.001

History of hypertension (%)

30,960 (14.8)

574 (43.7)

 < 0.001

32,190 (27.1)

734 (59.2)

 < 0.001

16,057 (49.5)

632 (75.8)

 < 0.001

History of dyslipidemia (%)

87,095 (41.6)

711 (54.1)

 < 0.001

67,540 (56.9)

824 (66.5)

 < 0.001

23,302 (71.9)

671 (80.5)

 < 0.001

Medications

 β-blockers (%)

1391 (0.7)

66 (5.0)

 < 0.001

2068 (1.7)

95 (7.7)

 < 0.001

1576 (4.9)

127 (15.2)

 < 0.001

 ACEs and ARBs (%)

7750 (3.7)

353 (26.9)

 < 0.001

9709 (8.2)

449 (36.2)

 < 0.001

8054 (24.8)

448 (53.7)

 < 0.001

 CCBs (%)

7318 (3.5)

312 (23.7)

 < 0.001

9715 (8.2)

421 (34.0)

 < 0.001

6728 (20.7)

378 (45.3)

 < 0.001

 Diuretics (%)

1260 (0.6)

46 (3.5)

 < 0.001

1774 (1.5)

97 (7.8)

 < 0.001

1501 (4.6)

92 (11.0)

 < 0.001

 Statins (%)

5014 (2.4)

232 (17.7)

 < 0.001

7212 (6.1)

326 (26.3)

 < 0.001

7050 (21.7)

381 (45.7)

 < 0.001

 Antiplatelet agents (%)

879 (0.4)

327 (24.9)

 < 0.001

1177 (1.0)

405 (32.7)

 < 0.001

1508 (4.7)

425 (51.0)

 < 0.001

OHAs (%)

      

13,566(41.8)

491 (58.9)

 < 0.001

GLP-1 (%)

      

105 (0.3)

8 (1.0)

0.002

Insulin (%)

      

989 (3.1)

44 (5.3)

 < 0.001

  1. Data are presented as mean ± SD or median (interquartile range), n (%). International Federation of Clinical Chemistry and Laboratory Medicine units
  2. ACEs angiotensin-converting-enzyme inhibitors, ARBs angiotensin-receptor blockers, BMI body mass index, Border borderline glycemia, CCBs calcium-channel blockers, CVD cerebrovascular disease, DBP diastolic blood pressure, FPG fasting plasma glucose, GLP-1 glucagon-like peptide 1 receptor agonists, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, OHAs oral hypoglycemic agents, SBP systolic blood pressure
  3. Hypertension was defined as SBP > 140 mmHg, DBP > 90 mmHg, or treatment for hypertension
  4. Dyslipidemia was defined as LDL cholesterol > 3.6 mmol/L, HDL cholesterol < 1.0 mmol/L, triglycerides > 1.6 mmol/L, or treatment for dyslipidemia
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840